Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447469 · ClinicalTrials.gov registry record · Phase 2
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
A Phase 2 study, sponsored by Kiniksa Pharmaceuticals International.
- Completed
- Registry status
- Phase 2
- Development phase
- 814
- Enrollment target
NCT04447469 is a Phase 2 study that has completed, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 814 participants.
The verdict
NCT04447469, a Phase 2 study, has completed, sponsored by Kiniksa Pharmaceuticals International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 814 participants
- Enrollment target
Study Summary
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
Interventions
- OTHER Placebo
- DRUG mavrilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 814 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447469
The ClinicalTrials.gov registry entry for NCT04447469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 814 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiniksa Pharmaceuticals International, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04447469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04447469 about?
NCT04447469 is a clinical study titled "Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation". Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
What is the current status of trial NCT04447469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 814 participants. The study started on 2020-07-28. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT04447469?
The interventions under investigation include: Placebo (OTHER), mavrilimumab (DRUG).
Who is sponsoring clinical trial NCT04447469?
This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.